S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Merus Stock Price, News & Analysis (NASDAQ:MRUS)

$23.93
-0.83 (-3.35%)
(As of 12/8/2023 ET)
Compare
Today's Range
$23.76
$24.92
50-Day Range
$20.06
$25.13
52-Week Range
$12.44
$27.70
Volume
344,335 shs
Average Volume
383,214 shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60

Merus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.4% Upside
$44.60 Price Target
Short Interest
Bearish
11.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.14mentions of Merus in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$14,133 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.61) to ($3.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

803rd out of 932 stocks

Pharmaceutical Preparations Industry

377th out of 431 stocks


MRUS stock logo

About Merus Stock (NASDAQ:MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock Price History

MRUS Stock News Headlines

Merus' (MRUS) "Buy" Rating Reaffirmed at Needham & Company LLC
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Merus: Buy Rating Justified by Clinical Progress and Market Potential
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Merus NV MRUS
Merus Announces Business Update Conference Call
See More Headlines
Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRUS
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.60
High Stock Price Target
$49.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+86.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-131,190,000.00
Net Margins
-387.00%
Pretax Margin
-381.43%

Debt

Sales & Book Value

Annual Sales
$41.59 million
Book Value
$5.34 per share

Miscellaneous

Free Float
55,250,000
Market Cap
$1.38 billion
Optionable
Not Optionable
Beta
0.82
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Sven Ante Lundberg M.D. (Age 60)
    CEO, President & Executive Director
    Comp: $953.06k
  • Mr. Gregory D. Perry (Age 63)
    CFO & Principal Financial Officer
    Comp: $63.76k
  • Mr. Peter B. Silverman J.D. (Age 45)
    EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
    Comp: $601.19k
  • Dr. Hui Liu Ph.D. (Age 56)
    Chief Business Officer, Executive VP & Head of Merus U.S.
    Comp: $597.7k
  • Dr. Andrew Joe M.D. (Age 57)
    Chief Medical Officer & Senior VP
    Comp: $692.74k
  • Dr. Hennie Hoogenboom
    Co-Founder and Scientific Advisor
  • Harry Shuman
    Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D. (Age 58)
    CTO & Executive VP
    Comp: $348.73k
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
    Chief Scientific Officer & Senior VP
  • Ms. Jillian Connell
    VP of Investor Relations & Corporate Communications














MRUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Merus stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings
or view top-rated stocks.

What is Merus' stock price target for 2024?

11 Wall Street research analysts have issued 12 month target prices for Merus' shares. Their MRUS share price targets range from $35.00 to $49.00. On average, they predict the company's stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price.
View analysts price targets for MRUS
or view top-rated stocks among Wall Street analysts.

How have MRUS shares performed in 2023?

Merus' stock was trading at $15.47 at the beginning of 2023. Since then, MRUS stock has increased by 54.7% and is now trading at $23.93.
View the best growth stocks for 2023 here
.

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our MRUS earnings forecast
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) posted its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.30. The biotechnology company had revenue of $11.03 million for the quarter, compared to analysts' expectations of $10.96 million. Merus had a negative net margin of 387.00% and a negative trailing twelve-month return on equity of 63.39%.

What ETFs hold Merus' stock?

ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Merus own?
When did Merus IPO?

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.72%), Federated Hermes Inc. (5.00%), Wellington Management Group LLP (4.74%), RTW Investments LP (3.46%), Braidwell LP (3.29%) and Lynx1 Capital Management LP (1.99%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg.
View institutional ownership trends
.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MRUS) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -